<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="abstract" dtd-version="1.0" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CC</journal-id>
<journal-id journal-id-type="nlm-ta">Cardiol Croat</journal-id>
<journal-title-group>
<journal-title>Cardiologia Croatica</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Cardiol. Croat.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">1848-543X</issn>
<issn pub-type="epub">1848-5448</issn>
<publisher><publisher-name>Croatian Cardiac Society</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">CC 2019 14_9-10_221</article-id>
<article-id pub-id-type="doi">10.15836/ccar2019.221</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Extended Abstract</subject></subj-group>
</article-categories>
<title-group>
<article-title>Survival of heart failure patients with reduced and preserved ejection fraction is not different!</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5175-8941</contrib-id><name><surname>Durak-Nalbanti&#x0107;</surname><given-names>Azra</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1198-540X</contrib-id><name><surname>D&#x017E;ubur</surname><given-names>Alen</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7977-9819</contrib-id><name><surname>Serdarevi&#x0107;</surname><given-names>Nafija</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4967-7616</contrib-id><name><surname>Hamzi&#x0107;-Mehmedba&#x0161;i&#x0107;</surname><given-names>Aida</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7647-2723</contrib-id><name><surname>Zvizdi&#x0107;</surname><given-names>Faris</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>Hod&#x017E;i&#x0107;</surname><given-names>Enisa</given-names></name><ext-link ext-link-type="uri" xlink:href="https://www.orcid.org/0000-0002-7436-7708">https://www.orcid.org/0000-0002-7436-7708</ext-link></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3755-0968</contrib-id><name><surname>Vu&#x010D;ijak-Grgurevi&#x0107;</surname><given-names>Marina</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5374-0892</contrib-id><name><surname>Begi&#x0107;</surname><given-names>Alden</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1907-9017</contrib-id><name><surname>Mla&#x0107;o</surname><given-names>Akif</given-names></name></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9369-5571</contrib-id><name><surname>Gljiva-Gogi&#x0107;</surname><given-names>Zenisa</given-names></name></contrib>
<aff id="aff1">Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>ADDRESS FOR CORRESPONDENCE: Azra Durak-Nalbanti&#x0107;, Bolni&#x010D;ka 25, 71 000 Sarajevo, Bosnia and Herzegovina. / Phone: +38761221199 / Email: <email xlink:href="azradurak@yahoo.com">azradurak@yahoo.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>10</month><year>2019</year></pub-date>
<volume>14</volume>
<issue>9-10</issue>
<fpage>221</fpage>
<lpage>221</lpage>
<history>
<date date-type="received"><day>10</day><month>07</month><year>2019</year></date>
<date date-type="accepted"><day>16</day><month>09</month><year>2019</year></date>
</history>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Croatian Cardiac Society</copyright-holder>
</permissions>
<kwd-group kwd-group-type="author"><title>KEYWORDS: </title><kwd>heart failure</kwd><kwd>mortality</kwd></kwd-group>
</article-meta>
</front>
<body>
<p><bold>Introduction</bold>: A progress in the management of cardiovascular disease leads to a decrease in mortality, but heart failure (HF) seems to be an exception. Today, the rate of rehospitalization and mortality after acute heart failure is still very high. Lower ejection fraction (EF) means worse prognosis, but recent studies are reporting that HF patients with preserved EF have no better survival compared to patients with reduced EF (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>). Goal: to investigate a possible difference in the outcome of HF patients with reduced (HFREF) and preserved ejection fraction (HFPEF).</p>
<p><bold>Patients and Methods</bold>: In 222 patients hospitalized in acute HF (138 with reduced EF and 74 with preserved EF) were determined routine laboratory test, including BNP. The LVEF cutoff for diagnosing of HFPEF was above 45%. Patients were followed for the next 18 months for the occurrence of 1. readmission due to repeat decompensation and 2. mortality.</p>
<p><bold>Results</bold>: BNP at discharge was higher in HFREF compared to HFPEF group [699.3 (271.8-1519.1) pg/ml vs 263.3 (134.4-502.2) pg/ml, p &lt;0.001]. During 18-month follow-up 129 patients (58.11%) were readmitted due to decompensation, but there was no significant difference between group: in HFREF group was hospitalized 87 (63.04%) patients compared to 42 (50%) patients in HFPEF group (p=0.077). There was no difference in the rate of readmission in 1-month (p=0.7), 6-month (p=0.24), and 12-month follow up (p=0.16) in HFREF vs HFPEF group. In Kaplan-Meier curve there was no significant difference in the mean time of the occurrence of readmission due to decompensation: in HFREF group 2.2 (95% CI=1.58-2.8) months and in HFPEF group 2.33 (95% CI=1.3-3.4) months (p=0.89) (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>). In HFREF 18-month survival was 43.5% (60/138) and in HFPEF group was 56.0% (47/84) and the difference was not significant (p=0,096). In the Kaplan-Meier curve, there was no difference in time of survival in 18-month follow-up (p=0.9): mean time of survival in HFREF was 3.8 (95% CI=3.0-4.7) months and in HFPEF 3.75 (95% CI=2.5-5.0) months (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref>). There was no difference in mortality in 1-month (p=0.8), 6-month (p=0.16) and 12-month follow up (p=0.08).</p>
<fig id="f1" position="float" fig-type="figure"><label>FIGURE 1</label><caption><p>Admission due to decompensated heart failure in the group of heart failure patients with reduced (HFREF) and preserved ejection fraction (HFPEF).</p></caption><graphic xlink:href="CC201914_9-10_221-f1"></graphic></fig>
<fig id="f2" position="float" fig-type="figure"><label>FIGURE 2</label><caption><p>Kaplan-Meier survival curve in in the group of heart failure patients with reduced (HFREF) and preserved ejection fraction (HFPEF) in an 18-month period.</p></caption><graphic xlink:href="CC201914_9-10_221-f2"></graphic></fig>
<p><bold>Conclusion</bold>: Rate of rehospitalization due to decompensation and mortality is not different between HFREF and HFPEF group. Preserved EF is not related to better survival in patients with HF.</p>
</body>
<back>
<ref-list>
<title>LITERATURE</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>KS</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Matsouaka</surname><given-names>RA</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Heidenreich</surname><given-names>PA</given-names></name><name><surname>Hernandez</surname><given-names>AF</given-names></name><etal/></person-group> <article-title>Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.</article-title> <source>J Am Coll Cardiol</source>. <year>2017</year> Nov 14;<volume>70</volume>(<issue>20</issue>):<fpage>2476</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2017.08.074</pub-id><pub-id pub-id-type="pmid">29141781</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
